303A COLLEGE ROAD EAST, PRINCETON, NJ
Annual Report to Security Holders
PDS Biotechnology Enters $6M Securities Purchase Agreement with YA II PN, LTD.
Other Events
Earnings Release
Material disclosure
Investor Presentation
Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC)
Q1
Amended Annual Report
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
PRE 14A
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Definitive Revised Proxy Statement